Overview

Safety and Efficacy of Bimatoprost Timolol Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension

Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of once daily administered 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution compared with once daily administered 0.03% Bimatoprost Ophthalmic Solution and once daily administered 0.5% Timolol Ophthalmic Solution concurrently in patients with open-angle glaucoma or ocular hypertension
Phase:
N/A
Details
Lead Sponsor:
Allergan
Treatments:
Bimatoprost
Ophthalmic Solutions
Pharmaceutical Solutions
Timolol